Immodulon Therapeutics Limited

University of Colorado

Laura Rosa Brunet

Charles Akle

Christopher A Lowry

An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, selected from a cell, protein, peptide, antibody or antigen binding fragment thereof, directed against CTLA-4, PD-1, PD-L1 and combinations thereof, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator comprises a whole cell, for example,or

Checkpoint inhibitor and a whole cellfor use in cancer therapy

Compounds for use in the treatment of sepsis and/or the prevention or treatment of post-sepsis syndrome.

Growing community of inventors

Uxbridge, United Kingdom

Laura Rosa Brunet